Abstracts tagged "Uric Acid, Urate"

Abstract Number: 0279 • ACR Convergence 2024
Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Charles Leroy¹, Nghia Pham², François Brial³, Brenda Kischkel⁴, gwénaêlle Jayat⁵, Elena Ishow⁶, Christèle Combes⁷, Leo Joosten⁴, Augustin Latourte⁸, Pascal Richette⁹ and Hang-Korng Ea¹⁰, ¹Inserm 1132 / Université Paris Cité, levallois-perret, France, ²INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, ³Inserm 1132/ Université Paris Cité, Paris, France, ⁴Radboudumc, Nijmegen, Netherlands, ⁵Université Paris cité / Inserm 1132, paris, France, ⁶Université de Nantes / Ceisam, Nantes, France, ⁷INP-ENSIACET, Toulouse, France, ⁸AP-HP, Paris, France, ⁹Lariboisière Hospital, Paris, France, ¹⁰Université Paris Cité, INSERM UMR 1132 BIOSCAR, Paris, France
Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Frank Fan¹, Riyong Liu¹ and Yu Wang², ¹Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), ²Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 2127 • ACR Convergence 2024
Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
Isabella Silvestre Ignarro¹, Gabriela Tieme Ochikubo², Liliam Takayama³, Valeria de falco Caparbo², Camille Pinto Figueiredo², Marcos Rafael Nogueira Cavalcanti¹, Angelita Gomes De Souza¹, Isabela Judith Martins Bensenor¹, Ricardo Fuller¹ and Diogo Domiciano⁴, ¹Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, São Paulo, SP, Brazil, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil
Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…
Abstract Number: 0907 • ACR Convergence 2024
Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol
Niamh Fanning¹, Murray Cadzow², Ruth Topless³, Chris Frampton⁴, Nicola Dalbeth⁵, Tony Merriman⁶ and Lisa Stamp⁴, ¹University of Otago, Christchurch, New Zealand, ²University of Otago, Dunedin 9054, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Hilde B Hammer¹, Lars F Karoliussen¹, Lene Terslev², Espen A. Haavardsholm³ and Tillmann Uhlig¹, ¹Diakonhjemmet hospital, Oslo, Norway, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…
Abstract Number: 1085 • ACR Convergence 2024
Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Ashish Kumar¹, Ali Hariri¹, Yunjung Lee² and Minhyung Lee², ¹LG Chem Life Sciences USA, Boston, MA, ²LG Chem, Seoul, Republic of Korea
Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…
Abstract Number: 1090 • ACR Convergence 2024
Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy
Naomi Schlesinger¹, Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux³ and Peter Lipsky⁴, ¹University of Utah, Salt Lake City, UT, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., Deerfield, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
Abstract Number: 1091 • ACR Convergence 2024
Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
Chamaya De Silva¹, César Díaz², Gregory Gamble³, Anne Horne³, Anthony Doyle³, Lisa Stamp⁴ and Nicola Dalbeth³, ¹Health NZ Waitemata, Auckland, New Zealand, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: In gout, monosodium urate (MSU) crystal deposition occurs preferentially at certain joints, most frequently the first metatarsophalangeal (MTP) joint. Dual energy CT (DECT) allows…
Abstract Number: 1878 • ACR Convergence 2024
The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal², SRIKAR SAMA³ and candice reyes⁴, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³University of California San Francisco Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Gout is the most common form of inflammatory arthropathy. It occurs due to urate crystal deposition within the joint space, usually in the setting…
Abstract Number: 1885 • ACR Convergence 2024
Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis
Bo Chen¹ and Qibing Xie², ¹Chenbo, Chendu, Sichuan, China, ²Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…
Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Janis Timsans¹, Jenni Kauppi¹, Anne Kerola², Vappu Rantalaiho³, Hannu Kautiainen⁴ and Markku Kauppi², ¹Päijät-Häme Central Hospital, Lahti, Finland, ²Päijät-Häme Central Hospital, University of Helsinki, Lahti, Finland, ³Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ⁴Folkhälsan Research Center, Helsinki, Finland
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…
Abstract Number: 2005 • ACR Convergence 2024
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Puja Khanna¹, Vibeke Strand², Atul Singhal³, Herbert Baraf⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Sheldon Leung⁵, Hugues Santin-Janin⁷, Aletta Falk⁸ and Alan Kivitz⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Sobi, Stockholm, Sweden, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 1816 • ACR Convergence 2023
Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver
Janis Timsans¹, Jenni Kauppi¹, Hannu Kautiainen² and Markku Kauppi³, ¹Päijät-Häme Central Hospital, Lahti, Finland, ²University of Helsinki, Folkhälsan Research Center, Helsinki, Finland, ³University of Helsinki, Helsinki, Finland
Background/Purpose: Elevated serum uric acid (SUA) level is rather prevalent in the general population, and it is associated with numerous comorbidities and mortality. Etiology of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].